Selexipag treatment for pulmonary arterial hypertension associated with congenital heart disease after defect correction: insights from the randomised controlled GRIPHON study.
Fiche du document
- doi: 10.1002/ejhf.1375
- issn: 1388-9842
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/doi/10.1002/ejhf.1375
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/pmid/30632656
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/eissn/1879-0844
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/urn/urn:nbn:ch:serval-BIB_E88556185F8F2
info:eu-repo/semantics/openAccess , CC BY-NC-ND 4.0 , https://creativecommons.org/licenses/by-nc-nd/4.0/
Sujets proches
Congenital heart malformations Congenital cardiac disease Congenital heart abnormalities Congenital cardiac anomalies Congenital cardiac malformations Heart diseases, Congenital Heart--Diseases, Congenital Congenital heart defects Congenital cardiac defects Blood pressure, High Vascular hypertension High blood pressureCiter ce document
M. Beghetti et al., « Selexipag treatment for pulmonary arterial hypertension associated with congenital heart disease after defect correction: insights from the randomised controlled GRIPHON study. », Serveur académique Lausannois, ID : 10.1002/ejhf.1375
Métriques
Partage / Export
Résumé
Patients with pulmonary arterial hypertension associated with congenital heart disease (CHD-PAH) after defect correction have a poor prognosis compared with other CHD-PAH patients. Therefore, it is important that these patients are treated as early and effectively as possible. Evidence supporting the use of PAH therapies in patients with corrected CHD-PAH from randomised controlled trials is limited. The purpose of these analyses was to characterise the corrected CHD-PAH patients from the GRIPHON study and examine the response to selexipag. Out of the 110 patients diagnosed with corrected CHD-PAH, 55 had atrial septal defects, 38 had ventricular septal defects, 14 had persistent ducti arteriosus, and 3 had defects not further specified. Hazard ratios (HR) and 95% confidence intervals (CI) for the primary composite endpoint were calculated using Cox proportional hazard models. Compared with the non-CHD patients from GRIPHON, patients with corrected CHD-PAH were slightly younger, with a greater proportion being treatment-naive and in World Health Organization functional class I/II. The rate of the primary composite endpoint of morbidity/mortality was lower in patients with corrected CHD-PAH who were treated with selexipag compared with those treated with placebo (HR 0.58; 95% CI 0.25, 1.37). The most common adverse events were those known to be related to selexipag. These post-hoc analyses of GRIPHON provide valuable information about a large population of patients with corrected CHD-PAH, and suggest that selexipag may delay disease progression and was well-tolerated in patients with corrected CHD-PAH.